This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gallen, I. Search for Related Content Social Bookmarking                   What's this?

Review: The evolution of insulin treatment in type 1 diabetes: the advent of analogues

Diabetes Centre, Wycombe Hospital, High Wycombe, Buckinghamshire, HP11 2TT, UK, ian.gallen{at}sbucks.nhs.uk

Treating patients with type 1 diabetes to near-normal glycaemic levels significantly reduces the risk of microvascular complications and improves patient outcomes. Consequently, achieving and maintaining optimal glycaemic control is a key therapeutic aim and clear guidance regarding glycaemic targets now exists. The challenge is to achieve this level of control in routine clinical practice whilst minimising the treatment-related adverse events of hypoglycaemia and weight gain. The development of both rapid- and long-acting insulin analogues offers the potential to meet this challenge, with results from clinical trials indicating that analogue insulins have therapeutic benefits over older insulin preparations. However, it is important to see if these benefits can be repeated in non-clinical trial patient populations and, therefore, this article summarises the results from prospective audits of introducing insulin lispro and insulin glargine into routine clinical practice in patients with type 1 diabetes.

Key Words: insulin analogues • Iispro • glargine • type 1 diabetes.

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 6, 378-381 (2004)
DOI: 10.1177/14746514040040060301


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?